$PLX News

Protalix BioTherapeutics, Inc. (PLX) Q1 2026 Earnings Call Transcript

CORRECTION: Protalix BioTherapeutics Q1 EPS $0.22 Beats $0.06 Estimate, Sales $33.750M Beat $11.468M Estimate

Transcript: Protalix BioTherapeutics Q1 2026 Earnings Conference Call

Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance

HC Wainwright & Co. Reiterates Buy on Protalix BioTherapeutics, Maintains $12 Price Target

Protalix BioTherapeutics, Inc. (PLX) Q4 2025 Earnings Call Transcript

Protalix BioTherapeutics shares are trading lower after the company reported worse-than-expected Q4 financial results.

Protalix BioTherapeutics shares are trading lower after the company reported worse-than-expected Q4 financial results.

Protalix BioTherapeutics Expects FY26 Total Revenue To Range From ~$78M To $83M Including $25M Milestone Which Protalix Is Entitled To From Chiesi

Protalix BioTherapeutics Q4 EPS $(0.06) Misses $0.04 Estimate, Sales $9.300M Miss $16.918M Estimate

Protalix BioTherapeutics And Chiesi Global Rare Diseases Announce European Commission Approval of Additional Dosing Regimen For Elfabrio

The European Commission Approves 2mg/kg Every-4-weeks Dosing Regimen For Chiesi And Protalix Biotherapeutics' Elfabrio (Pegunigalsidase Alfa) For Fabry Disease Patients Who Are Stable With An Enzyme Replacement Therapy

A March Decision That Could Change Protalix BioTherapeutics Outlook

Protalix BioTherapeutics shares are trading higher after the company and Chiesi Group's unit announced that the Committee for Medicinal Products for Human Use of the EMA has issued a positive opinion recommending approval of the 2mg/kg E4W dosing regimen for Elfabrio in Fabry disease adult patients.

Chiesi Group's Unit And Protalix BioTherapeutics Say CHMP Of EMA Issues Positive Opinion Recommending Approval Of 2mg/Kg E4W Dosing Regimen For Elfabrio In Fabry Disease Adult Patients Stable With ERT Treatment

Protalix BioTherapeutics Letter to Stockholders

Protalix Bets on Gout and Rare Kidney Diseases as It Eyes New Drug Launches in 2026

PLX: Secarna’s Antisense Oligonucleotide Discovery Collaboration

Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement

Protalix Biotherapeutics Announced A Collaboration With Secarna Pharmaceuticals For The Discovery Of Novel Antisense Oligonucleotide Therapies Against Multiple Targets For Rare Renal Indications, Deal Terms Were Not Disclosed